NHS England approves use of F/TAF as alternative PrEP
1 June 2023. Related: HIV prevention and transmission.
Simon Collins, HIV i-Base
On 24 May 2023, NHS England updated guidelines on PrEP to include tenofovir alafenomide (TAF) as a component of PrEP.
Previously, PrEP was only reimbursed for generic formulations of tenofovir disoproxil (TD).
In both cases, TD or TAF need to be used in a combination tablet that also includes emtricitabine (FTC).
F/TAF is now approved for cases where preexisting bone or kidney disease limits the use of TD.
The paper estimates that this might affect from 400 to 700 people currently in need of this second-line PrEP. This estimate is based on 40,000 to 70,000 people currently using PrEP in the UK.
Reference
NHS England. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV. (24 May 2023).
https://www.england.nhs.uk/publication/reimbursement-for-the-use-of-generic-drugs-for-pre-exposure-prophylaxis-prep-for-the-prevention-of-hiv/